Skip to content
OpenCapital
Get started

Indivior Pharmaceuticals, Inc. INDV Current Debt

Current Debt at other companies

Alkermes logo
AlkermesALKS
——

Other financials

Income statement

See full
Revenue$317.0M+19.2%
Gross profit$277.0M+24.8%
Operating income$137.0M+108%
Net income$89.0M+89.4%
EPS (diluted)$0.69+81.6%

Balance sheet

See full
Cash & equivalents$175.0M-53.0%
Total debt$509.0M+37.6%
Total equity-$144.0M+49.5%
Total assets$1.2B-12.9%

Cash flow

See full
Operating cash flow-$9.0M-112%
CapEx$20.0M+300%
Free cash flow-$29.0M-141%

Valuation

See full
Market cap$4.53B+213%
Enterprise value$4.86B+242%
P/E18×—
P/S3.5×+2.3×

Profitability

See full
Gross margin81.3%+1.5pp
Operating margin25.8%+23.3pp
Net margin19.4%+18.9pp
FCF margin-14.9%—

Returns & leverage

See full
Return on equity-117%—
Debt / equity-3.5×—
Current ratio0.9×0.0×

Where this comes from

Reported directly by Indivior Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Indivior Pharmaceuticals, Inc. ’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Indivior Pharmaceuticals, Inc. 's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Indivior Pharmaceuticals, Inc. 's current debt?
Indivior Pharmaceuticals, Inc. (INDV) reported current debt of $0 in Q1 2026.
How has Indivior Pharmaceuticals, Inc. 's current debt changed year-over-year?
Indivior Pharmaceuticals, Inc. 's current debt decreased by 100.0% year-over-year, from $18M to $0.
What is the long-term trend for Indivior Pharmaceuticals, Inc. 's current debt?
Over 2 years (2023 to 2025), Indivior Pharmaceuticals, Inc. 's current debt has grown at a 210.9% compound annual growth rate (CAGR), from $3M to $29M.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.